What is RxMapper?
RxMapper operates as a personalized medication platform and telehealth service, developed in collaboration with Mayo Clinic. The company leverages DNA analysis to determine the most effective medications for individuals, aiming to enhance health outcomes and reduce healthcare expenditures. Its services are tailored for a broad audience, including employees, employers, health plans, brokers, consultants, and pharmacists. By integrating DNA sequencing with telehealth consultations, RxMapper provides precise medication guidance based on a patient's unique genetic profile, covering over 6,500 commercial drugs to improve treatment efficacy across various medical conditions.
How much funding has RxMapper raised?
RxMapper has raised a total of $5.7M across 1 funding round:
Other Financing Round
$5.7M
Other Financing Round (2024): $5.7M, investors not publicly disclosed
What's next for RxMapper?
The recent major strategic investment positions RxMapper for substantial growth and market expansion. This capital injection, part of its $5.7M in total financing, will likely fuel advancements in its proprietary DNA analysis technology and broaden the reach of its telehealth services. RxMapper's focus on personalized medicine, supported by its collaboration with Mayo Clinic, suggests a strategic direction towards becoming a leader in precision pharmacotherapy, potentially leading to further partnerships and scaling of its employer and health plan offerings.
See full RxMapper company page
